Key Highlights
- Revenue was USD 815.3 million against an estimate of USD 820.96 million.
- Operating income was USD 85.6 million, against USD 105.7 million a year earlier.
- The Idaho hospital sale closed with consideration of approximately USD 796.6 million.
- The amended Merger provides USD 25.00 per share in cash.
Surgery Partners (NASDAQ:SGRY) reported third quarter 2026 Revenue of USD 815.3 million, against an estimate of USD 820.96 million and USD 821.5 million in the third quarter of 2025. The loss per share attributable to common stockholders was USD 0.16, compared with a USD 0.18 loss a year earlier.
Net income was USD 14.1 million, compared with USD 25.3 million. After Net Income attributable to non-controlling interests of USD 35.2 million, against USD 48.0 million, the net loss attributable to Surgery Partners was USD 21.1 million, against USD 22.7 million.
Costs and Operating Income
Cost of revenues was USD 630.3 million, compared with USD 626.2 million. Salaries and benefits were USD 239.8 million, compared with USD 242.8 million, and supplies were USD 214.1 million, compared with USD 208.9 million. General and administrative expenses were USD 40.6 million, compared with USD 22.4 million.
Transaction and integration costs were USD 22.6 million, compared with USD 12.6 million. Operating Income was USD 85.6 million, compared with USD 105.7 million. Interest expense, net, was USD 67.9 million, compared with USD 74.9 million, and the filing attributes the USD 7.0 million decrease primarily to reduced borrowings on the Revolver.
Nine-Month Results and Liquidity
For the nine months ended September 30, 2026, revenue was USD 2.48 billion, compared with USD 2.42 billion, and operating income was USD 253.5 million, against USD 279.3 million. The loss per share was USD 0.56, against USD 0.50.
The company had cash and cash equivalents of USD 354.5 million and USD 692.8 million of borrowing capacity under the Revolver as of September 30, 2026. Cash and cash equivalents were USD 239.9 million at the prior Balance Sheet date.
Idaho Sale and Merger Agreement
On September 14, 2026, the company completed the previously announced sale of its ownership interests in Mountain View Hospital, LLC, Idaho Falls Community Hospital, LLC and associated subsidiaries to Intermountain Health. The company received aggregate consideration of approximately USD 796.6 million, consisting of consideration for the ownership interests sold and the termination of its management agreement with Mountain View Hospital.
On October 23, 2026, the company entered into an Agreement and Plan of Merger with Spyglass Topco, LLC, Spyglass Merger Subsidiary, Inc. and, for limited purposes, Bon Secours Mercy Health, Inc. The agreement was amended on November 8, 2026. Under the amended agreement, each eligible share of common stock would be converted into the right to receive USD 25.00 in cash, without interest.
If stockholder approval has been obtained but the merger has not occurred by March 1, 2027, eligible stockholders would receive additional monthly cash consideration under the amendment. If the merger is completed, the common stock would be Delisted from the Nasdaq Global Select Market and deregistered.
Surgery Partners Q3 2026 Earnings: Key Takeaways
Surgery Partners reported third quarter 2026 revenue of USD 815.3 million and operating income of USD 85.6 million. The filing also describes the completed Idaho sale and an amended merger agreement at USD 25.00 per share in cash.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...